0JSY Panoramica delle azioni Labcorp Holdings Inc. fornisce servizi di laboratorio. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Labcorp Holdings Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Labcorp Holdings Prezzi storici delle azioni Prezzo attuale dell'azione US$229.98 Massimo di 52 settimane US$248.07 Minimo di 52 settimane US$192.43 Beta 1.04 Variazione di 1 mese -3.79% Variazione a 3 mesi 4.23% Variazione di 1 anno 2.66% Variazione a 3 anni -25.33% Variazione a 5 anni 37.30% Variazione dall'IPO 30.37%
Notizie e aggiornamenti recenti
Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order Through Physicians Dec 18
Labcorp Holdings Inc. (NYSE:LH) completed the acquisition of Select Outreach Services of Ballad Health. Dec 13 Labcorp Holdings Inc. Announces Chief Financial Officer Changes
Upcoming dividend of US$0.72 per share Nov 19
Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023) Oct 25
Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024 Oct 24 Vedi altri aggiornamenti
Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order Through Physicians Dec 18
Labcorp Holdings Inc. (NYSE:LH) completed the acquisition of Select Outreach Services of Ballad Health. Dec 13 Labcorp Holdings Inc. Announces Chief Financial Officer Changes
Upcoming dividend of US$0.72 per share Nov 19
Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023) Oct 25
Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024 Oct 24 Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test
Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024 Sep 25
Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million. Sep 19
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million. Sep 17
Upcoming dividend of US$0.72 per share Aug 22
CFO & Executive VP recently sold US$3.4m worth of stock Aug 20
Insider recently sold US$2.8m worth of stock Aug 08
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q). Aug 07
Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx Aug 02
Second quarter 2024 earnings released: EPS: US$2.44 (vs US$1.75 in 2Q 2023) Aug 02
Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024 Aug 01
Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024 Jul 25
Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 02
Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials Jun 18
Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio Jun 05
Upcoming dividend of US$0.72 per share May 17
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy May 16
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B Apr 30
First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.35 in 1Q 2023) Apr 26
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million. Apr 26
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw Apr 15
Dividend of US$0.72 announced Apr 14 Labcorp Declares Quarterly Dividend, Payable on June 12, 2024
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs Apr 10 Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research Apr 02
Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024 Mar 29
Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024 Mar 28
Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials Mar 20
Labcorp Launches Weight Loss Management Testing Solutions Mar 07
CFO & Executive VP recently sold US$4.4m worth of stock Feb 23
Upcoming dividend of US$0.72 per share Feb 19
Full year 2023 earnings released: EPS: US$4.35 (vs US$14.04 in FY 2022) Feb 16
Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024 Feb 16
Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia Jan 31
Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024 Jan 17
Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024 Jan 12
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company. Nov 21
Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test Nov 15
Upcoming dividend of US$0.72 per share at 1.5% yield Oct 31
Third quarter 2023 earnings released: EPS: US$2.12 (vs US$3.91 in 3Q 2022) Oct 27
Labcorp Declares a Cash Dividend, Payable on December 12, 2023 Oct 13
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc. Oct 06
Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023 Sep 30
Independent Director recently sold US$1.1m worth of stock Aug 11
Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc. Aug 04
Upcoming dividend of US$0.72 per share at 1.3% yield Jul 31
Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023 Jul 28
Second quarter 2023 earnings released: EPS: US$1.75 (vs US$3.89 in 2Q 2022) Jul 28
Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million. Jul 25
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health. Jul 14
Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company. Jul 12
Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023 Jun 30
Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board Jun 08
Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus Jun 01
Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire the outreach laboratory business and select assets of Providence Health & Services - Oregon. May 17
Upcoming dividend of US$0.72 per share at 1.3% yield May 10 Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer
First quarter 2023 earnings released: EPS: US$2.41 (vs US$5.28 in 1Q 2022) Apr 26
Insider recently sold US$1.3m worth of stock Feb 24
Full year 2022 earnings released: EPS: US$14.04 (vs US$24.58 in FY 2021) Feb 17
Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023 Feb 17
Now 21% undervalued Feb 16
Upcoming dividend of US$0.72 per share at 1.2% yield Feb 15
Laboratory Corporation of America Holdings to Report Q4, 2022 Results on Feb 16, 2023 Jan 19
Labcorp Declares Cash Dividend on Common Stock, Payable on March 13, 2023 Jan 13
Labcorp Announces Executive Changes Jan 06
Upcoming dividend of US$0.72 per share Nov 09
Third quarter 2022 earnings released: EPS: US$3.91 (vs US$6.10 in 3Q 2021) Oct 27
Laboratory Corporation of America Holdings Appoints Kirsten Kliphouse to Board of Directors Oct 14
Labcorp Declares Quarterly Dividend, Payable on December 9, 2022 Oct 13
Laboratory Corporation of America Holdings (NYSE:LH) acquired Certain Outreach Laboratory Assets from Certain Outreach Laboratory Assets. Oct 04
Laboratory Corporation of America Holdings to Report Q3, 2022 Results on Oct 27, 2022 Sep 28
Laboratory Corporation of America Holdings (NYSE:LH) acquired Clinical Outreach Laboratory Business and Select Related Assets of RWJBarnabas Health. Aug 24
Upcoming dividend of US$0.72 per share Aug 10
Senior VP & Chief Accounting Officer recently sold US$467k worth of stock Aug 04
Second quarter 2022 earnings released: EPS: US$3.89 (vs US$4.80 in 2Q 2021) Jul 29
Laboratory Corporation of America Holdings Launches Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test Jul 20 Laboratory Corporation of America Holdings to Report Q2, 2022 Results on Jul 28, 2022
Labcorp to Begin Testing for Monkeypox Using the U.S. Centers for Disease Control and Prevention’s Othopoxvirus Test Jul 07 Labcorp Launches New Test for People with Skin Cancer Laboratory Corporation of America Holdings (NYSE:LH) acquired Select Assets from the Clinical Outreach Business of AtlantiCare. May 10
First quarter 2022 earnings released: EPS: US$5.28 (vs US$7.89 in 1Q 2021) Apr 29
Labcorp Launches Convenient Home Diagnostic Test Collection Service in Collaboration With Getlabs Apr 23 Rendimenti per gli azionisti 0JSY GB Healthcare GB Mercato 7D -0.5% -0.05% -0.6% 1Y 2.7% -25.9% 3.1%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 0JSY ha superato il UK Healthcare che ha restituito -25.9 % nell'ultimo anno.
Rendimento vs Mercato: 0JSY ha eguagliato il mercato UK che ha restituito 3.1 % nell'ultimo anno.
Volatilità dei prezzi Is 0JSY's price volatile compared to industry and market? 0JSY volatility 0JSY Average Weekly Movement 2.9% Healthcare Industry Average Movement 5.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Prezzo delle azioni stabile: 0JSY non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 3% ) di 0JSY è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1995 61,975 Adam Schechter www.labcorp.com
Labcorp Holdings Inc. fornisce servizi di laboratorio. Opera attraverso due segmenti, Diagnostics Laboratories e Biopharma Laboratory Services. L'azienda offre vari test, come analisi chimiche del sangue, analisi delle urine, emocromo, tiroide, PAP, emoglobina A1C e vitamina D, antigeni specifici della prostata, malattie a trasmissione sessuale, epatite C, colture e procedure microbiologiche, test per l'abuso di alcol e altre sostanze.
Mostra di più Labcorp Holdings Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Labcorp Holdings con la sua capitalizzazione di mercato? 0JSY statistiche fondamentali Capitalizzazione di mercato US$19.19b Guadagni(TTM ) US$435.50m Ricavi(TTM ) US$12.71b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 0JSY Conto economico (TTM ) Ricavi US$12.71b Costo del fatturato US$9.16b Profitto lordo US$3.55b Altre spese US$3.11b Guadagni US$435.50m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 5.21 Margine lordo 27.92% Margine di profitto netto 3.43% Rapporto debito/patrimonio netto 83.2%
Come si è comportato 0JSY nel lungo periodo?
Vedi performance storica e confronto Dividendi
1.3% Rendimento attuale del dividendo
56% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/25 21:03 Prezzo dell'azione a fine giornata 2024/12/24 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Labcorp Holdings Inc. è coperta da 48 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Jasper Hellweg Argus Research Company Brian Kemp Dolliver Avondale Partners Eric Coldwell Baird
Mostra 45 altri analisti 
